TEVA AND ACTIVE BIOTECH TO INITIATE PIVOTAL PHASE III TRIAL

Contacts:

Teva:

Dan Suesskind

Chief Financial Officer

Teva Pharmaceutical Industries Ltd.

+ 972 2 589 28 40

Active Biotech:

Sven Andréasson

President & CEO

+46 46 19 20 49

George Barrett
President and CEO
Teva North America
+1 215 591 30 30

Tomas Leanderson

Chief Scientific Officer

+46 46 19 20 95

Liraz Kalif / Kevin Mannix
Teva Investor Relations
+972 3 926 72 81 / +1 215 591 89 12

Cecilia Hofvander

Manager Corporate Communication

+46 46 19 11 22

TEVA AND ACTIVE BIOTECH TO INITIATE PIVOTAL PHASE III TRIAL PROGRAM OF ORAL LAQUINIMOD FOR RELAPSING MULTIPLE SCLEROSIS

Anhänge

Teva: Dan Suesskind Chief Financial Officer Teva Pharmaceutical Industries Ltd. + 972 2 589 28 40	Active Biotech: Sven Andréasson President & CEO +46 46 19 20 49
George Barrett President and CEO Teva North America +1 215 591 30 30	Tomas Leanderson Chief Scientific Officer +46 46 19 20 95
Liraz Kalif / Kevin Mannix Teva Investor Relations +972 3 926 72 81 / +1 215 591 89 12	Cecilia Hofvander Manager Corporate Communication +46 46 19 11 22